StockNews.com assumed coverage on shares of T2 Biosystems (NASDAQ:TTOO – Free Report) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.
T2 Biosystems Price Performance
Shares of NASDAQ:TTOO opened at $0.32 on Monday. The stock’s 50-day simple moving average is $0.47 and its two-hundred day simple moving average is $2.21. T2 Biosystems has a 52-week low of $0.31 and a 52-week high of $6.95.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC acquired a new stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOO – Free Report) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems as of its most recent SEC filing. Hedge funds and other institutional investors own 23.18% of the company’s stock.
T2 Biosystems Company Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Further Reading
- Five stocks we like better than T2 Biosystems
- What is the MACD Indicator and How to Use it in Your Trading
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- How to Short a Stock in 5 Easy Steps
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- Profitably Trade Stocks at 52-Week Highs
- Delta Can Fly to New Highs in 2025; Here’s Why
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.